UK markets close in 56 minutes
  • FTSE 100

    7,020.79
    +72.80 (+1.05%)
     
  • FTSE 250

    22,206.23
    +39.09 (+0.18%)
     
  • AIM

    1,233.88
    -1.78 (-0.14%)
     
  • GBP/EUR

    1.1670
    +0.0033 (+0.28%)
     
  • GBP/USD

    1.4096
    -0.0048 (-0.34%)
     
  • BTC-GBP

    40,271.52
    +613.13 (+1.55%)
     
  • CMC Crypto 200

    1,543.09
    -20.74 (-1.33%)
     
  • S&P 500

    4,107.92
    -44.18 (-1.06%)
     
  • DOW

    33,977.04
    -292.12 (-0.85%)
     
  • CRUDE OIL

    66.51
    +1.23 (+1.88%)
     
  • GOLD FUTURES

    1,831.60
    -4.50 (-0.25%)
     
  • NIKKEI 225

    28,147.51
    -461.08 (-1.61%)
     
  • HANG SENG

    28,231.04
    +217.23 (+0.78%)
     
  • DAX

    15,197.58
    +77.83 (+0.51%)
     
  • CAC 40

    6,289.20
    +21.81 (+0.35%)
     

Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·4-min read
  • Oops!
    Something went wrong.
    Please try again later.

Altimmune (NASDAQ: ALT) began clinical testing of its intranasal COVID-19 vaccine candidate earlier this year. The University of Oxford recently began testing a nasal-spray version of the COVID-19 vaccine that it developed with big drugmaker AstraZeneca (NASDAQ: AZN). In this Motley Fool Live video recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not an intranasal COVID-19 vaccine from AstraZeneca could zap Altimmune's prospects.